tiprankstipranks
CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
US Market

CytoMed Therapeutics Limited (GDTC) Income Statement

Compare
8 Followers

CytoMed Therapeutics Limited Income Statement

Last quarter (Q2 2024), CytoMed Therapeutics Limited's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q2, CytoMed Therapeutics Limited's net income was $-807.96K. See CytoMed Therapeutics Limited’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 290.56K---$ 0.00
Gross Profit
$ 213.09K---$ 0.00
Operating Expenses
$ 3.12M----
Depreciation and Amortization
$ 77.47K----
EBITDA
$ -2.94M----
Operating Income
$ -2.91M----
Other Income/Expenses
$ -219.50K----
Pretax Income
$ -3.13M----
Net Income
$ -3.13M----
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.29$ -0.30$ -0.22$ -0.25$ -0.08
Diluted EPS
$ -0.29$ -0.30$ -0.22$ -0.25$ -0.08
Weighted Average Shares Outstanding
10.63M 7.92M 6.93M 5.90M 5.55M
Weighted Average Shares Outstanding (Diluted)
10.63M 7.92M 6.93M 5.90M 5.55M
Currency in USD

CytoMed Therapeutics Limited Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis